Hospital Hm Rosaleda Hm La Esperanza
- Address
- lock Available on a paid plan
Immune System Diseases
The rheumatology department at Hospital Hm Rosaleda Hm La Esperanza is advancing treatments for autoimmune conditions, notably rheumatoid arthritis, by evaluating innovative small‑molecule inhibitors and biologics aimed at reducing inflammation and improving patient outcomes.
- Evaluation of a TNFR1 signaling inhibitor in moderate‑to‑severe rheumatoid arthritis
- Assessment of anti‑inflammatory therapy for erosive hand osteoarthritis
- Investigation of novel agents targeting synovitis in knee osteoarthritis
The site is conducting 10 clinical studies with a team of 5 investigators, contributing valuable data to the field of immune‑mediated rheumatic diseases.
Musculoskeletal Diseases
Research at the department emphasizes pain management and joint health for conditions such as knee osteoarthritis, erosive hand osteoarthritis, and chronic non‑specific low back pain, testing new therapies that aim to alleviate symptoms and preserve joint structure.
- Pain reduction strategies for knee osteoarthritis
- Structural modification of the tibiofemoral compartment in osteoarthritic knees
- Dose‑response evaluation of treatments for chronic low back pain
- Therapeutic options for erosive hand osteoarthritis
These investigations support the goal of improving functional ability and quality of life for patients with musculoskeletal disorders.
Nutritional and Metabolic Diseases
The unit explores the link between excess body weight and joint degeneration, focusing on interventions that promote weight loss while reducing pain in individuals with overweight or obesity and concurrent knee osteoarthritis.
- Weight‑loss efficacy of combined pharmacologic and lifestyle programs in obese patients with knee osteoarthritis
- Impact of metabolic health improvement on osteoarthritis‑related pain
- Integrated approaches targeting obesity and joint inflammation
By addressing metabolic risk factors, the research aims to enhance long‑term joint health and overall well‑being.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Hm Rosaleda Hm La Esperanza
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with Hyperuricemia | LG Chem Ltd. | Phase III | Not Recruiting | Apr 2024 | Apr 2025 |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paracetamol | 3 | Unknown | 2021-11-09 | 2024-02-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.